Spineology to distribute BioDlogics products derived from amniotic tissue |

Spineology to distribute BioDlogics products derived from amniotic tissue

   

 

 

Spineology website    BioDlogics website

Spineology to Distribute BioDlogics Products (press release)

Spineology Inc., the innovator in anatomy conserving surgery technologies, today announced that it has entered into an agreement with BioDlogics to distribute that company’s line of allograft tissue forms.

“Spineology’s corporate focus on minimally invasive surgical techniques coupled with its growing direct sales force provides an attractive opportunity for us to expand our penetration in a growing market segment”

“BioDlogics’ products provide a very attractive complement to our current product line,” said John Booth, CEO for Spineology. “We believe that recent advances in regenerative medicine have the potential to significantly improve patient outcomes in numerous clinical applications. We look forward to working with BioDlogics to offer its line of novel allograft tissue to surgeons using our products.”

“Spineology’s corporate focus on minimally invasive surgical techniques coupled with its growing direct sales force provides an attractive opportunity for us to expand our penetration in a growing market segment,” said Greg Brophy, president of BioDlogics. “We are excited to work with Spineology as a distribution partner.”

About Spineology Inc.
Spineology Inc., the innovator in anatomy-conserving spine surgery, develops spinal implants and instruments. Spineology surgical techniques conserve spinal bone, ligament and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity and accelerating patient recovery. Learn more at spineology.com.

About BioDlogics, LLC
BioDlogics, LLC, is a biomedical company formed in 2005 to engage in the development and commercialization of novel wound covering products derived from amniotic tissue. Its research and development efforts are focused on the regenerative potential of amniotic tissue given its unique biologic structure, its rich source of proteins, growth factors and undifferentiated stem cells, and the unique immune privilege that characterizes its function in the body. From the recovery of tissue from live, healthy donors during childbirth to the development of new products that will improve patient outcomes, BioDlogics is committed to unlocking the regenerative potential of the human body.

Leave a Reply

Your email address will not be published. Required fields are marked *